B cell lymphoma 2/Bcl2
Rb, 0.5 ml Conc.
Technische Daten
Lagerung AK: | Store at 2 - 8 °C. Do not use after expiration date indicated on the vial. | Kontrolle: | Tonsil | Zelluläre Lokalisation: | Cytoplasmic | Fixierung: | 1) NOTOXhisto 2) Formalin | Anwendung AK: | IHC(p),IHC(f) | Immunogen: | Synthetic peptide of human Bcl-2 | Ig Unterklasse: | IgG | Spezies: | Rabbit | Klon: | Polyclonal | Format AK: | Concentrate | Reaktivität AK: | Human, others not tested. | Synonyme: | Apoptosis regulator Bcl 2, Apoptosis regulator Bcl2, AW986256, B cell CLL/lymphoma 2, B cell leukemia/lymphoma 2, B cell lymphoma 2, Bcl 2, Bcl-2, Bcl2, BCL2 protein, C430015F12Rik, D630044D05Rik, D830018M01Rik, Leukemia/lymphoma, B-cell, 2, Oncogene B-cell leukemia 2. | Verfügbar in folgenden Ländern: | world wide (except US) | Status: | IVD |
Beschreibung
This antibody recognizes the anti-apoptotic protein BCL2, which is useful in distinguishing between neoplastic and reactive follicular lymphoma (BCL2-negative). It indcates cancers of breast, prostate, ovary, endometrium and colon. A recently identified protein,designated Bax p21 (Bcl-associated X protein ), has extensive amino acid homology with Bcl-2. Overexpression of Bax accelerates apoptotic death induced by cytokine deprivation and it counters the death repressor activty of Bcl-2.
Literatur
[1] Hata AN, Engelman JA and Faber AC (2015): The
BCL2 Family: Key Mediators of the Apoptotic Response
to Targeted Anticancer Therapeutics. Cancer Discov.
5(5):475-87.
[2] Anderson MA, Huang D and Roberts A (2014):
Targeting BCL2 for the treatment of lymphoid
malignancies. Semin Hematol. 51(3):219-27.
[3] Vogler M (2014): Targeting BCL2-Proteins for the
Treatment of Solid Tumours. Adv Med. 2014:943648.
|